Samsung Bioepis seeks Europe approval for its Herceptin copy

SEOUL (Reuters) - Biosimilars maker Samsung Bioepis, part of South Korea's top conglomerate Samsung Group [SAGR.UL], said on Tuesday it is seeking regulatory approval in Europe to sell its copy of Roche's breast cancer drug Herceptin.